{"ok":true,"nota":{"id":"0f94173405a9ac6a","slug":"un-analisis-de-sangre-antes-del-tratamiento-ayuda-a-prever-cuanto-hues-0f9417","titulo":"Un análisis de sangre antes del tratamiento ayuda a prever cuánto hueso ganará la cadera con denosumab","resumen":"Investigadores midieron marcadores de renovación ósea en pacientes antes de iniciar denosumab y los siguieron a largo plazo. Crearon un índice que combina esos marcadores y lo compararon con la densidad mineral ósea de la cadera.","fuente":"medrxiv","fuenteNombre":"medRxiv · preprints","color":"#1f7a4d","autor":"Asada, T., Richardson, W., Tani, S., Ishikawa, M., Varnadore, P., Towatari, T., Passias, P., Kudo, Y., Alman, B., Ishika","url":"https://www.medrxiv.org/content/10.64898/2026.10.20.26366058v1?rss=1","imagen":"/hoy/portada/0f94173405a9ac6a","tema":"salud","subtemas":["osteoporosis","denosumab","densidad ósea","biomarcadores","tratamiento personalizado"],"entidades":["denosumab"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-22T00:00:00.000Z","indexTs":"2026-10-22T23:19:43.636Z","hash":"e0c6533a20e65048b4b5f6ee424e564205798932aa4e7fb91ea350f0c95314bb","tsa":{"time":"Oct 22 23:20:59 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Hay personas con osteoporosis que, al empezar el tratamiento, tienen menos recambio de hueso y responden más despacio, y el estudio permitiría detectarlas antes. Para ellas, saber de entrada que la mejora va a ser más lenta podría cambiar la forma de seguirlas. Son muchos los que toman el medicamento creyendo que va a funcionar igual para todos, y no siempre es así.","quienFirma":"Autores de la publicación (institución no identificada en el resumen)","confianza":"preprint","consulta":null},"sello":{"hash":"e0c6533a20e65048b4b5f6ee424e564205798932aa4e7fb91ea350f0c95314bb","sello":"5fec1164b4cb93e77b5e3b68508bebf4ab6b4ca30cd68fdcf08eeab8b55cb83c","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6576007,"aleatorio":"95dbaf32f50651e333ceec71d41e8fb48fb5366fda7d20abcbc7ea91ece96f50","tiempo":"2026-10-22T23:20:30.000Z"},"nist":{"cadena":2,"pulso":1995203,"salida":"8A13BF41CC085A093FFEA64CBB7EB887732A2613A6D9655D0453147066A38EB79E9EC218F3D2AC07553BF1FD20E0E18DC3AD27C19DD5DB9E691AB8B8E2BD47D3","tiempo":"2026-10-22T23:20:00.000Z"},"noAntes":"2026-10-22T23:20:30.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 22 23:20:59 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Pretreatment bone turnover status and long-term bone mineral density response to denosumab","descripcion":"Abstract Summary Pretreatment low-turnover status identified patients with attenuated total hip BMD gain after denosumab. Integrated assessment of bone resorption and formation markers may help stratify long-term hip response. Introduction Denosumab increases bone mineral density (BMD) and reduces fracture risk, but BMD response varies among patients. Given its potent antiresorptive action, denosumab may produce greater BMD gains in patients with higher pretreatment bone turnover; however, its relationship with long-term BMD response remains unclear. We developed a turnover index (TI) integrating bone resorption and formation markers and evaluated its association with BMD response trajectori","pubDate":"2026-10-22","url":"https://www.medrxiv.org/content/10.64898/2026.10.20.26366058v1?rss=1"},"indexado":"2026-10-22T23:19:43.636Z"}}